Moleculin Biotech Inc
MBRX3.980USD
-0.130-3.16%
Close 01/09, 16:00（ET）Quotes delayed by 15 min
7.88MMarket Cap
LossP/E TTM
More Details of Moleculin Biotech Inc Company
Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).
Moleculin Biotech Inc Info
Ticker SymbolMBRX
Company nameMoleculin Biotech Inc
IPO dateJun 02, 2016
CEOKlemp (Walter V)
Number of employees17
Security typeOrdinary Share
Fiscal year-endJun 02
Address5300 Memorial Dr Ste 950
CityHOUSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code77007
Phone17133005160
Websitehttps://moleculin.com/
Ticker SymbolMBRX
IPO dateJun 02, 2016
CEOKlemp (Walter V)
Company Executives of Moleculin Biotech Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Donald H. Picker, Ph.D.
Dr. Donald H. Picker, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
671.00
--
Mr. Robert E. George
Mr. Robert E. George
Independent Director
Independent Director
40.00
+1.00%
Mr. Michael D. Cannon
Mr. Michael D. Cannon
Independent Director
Independent Director
--
--
Mr. John Michael Climaco, Esq.
Mr. John Michael Climaco, Esq.
Independent Director
Independent Director
--
--
Ms. Elizabeth A. (Liz) Cermak
Ms. Elizabeth A. (Liz) Cermak
Independent Director
Independent Director
--
--
Dr. Joy Yan, LPN
Dr. Joy Yan, LPN
Independent Director
Independent Director
--
--
Mr. Walter V. Klemp
Mr. Walter V. Klemp
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Mr. Jonathan P. Foster
Mr. Jonathan P. Foster
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Donald H. Picker, Ph.D.
Dr. Donald H. Picker, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
671.00
--
Mr. Robert E. George
Mr. Robert E. George
Independent Director
Independent Director
40.00
+1.00%
Mr. Michael D. Cannon
Mr. Michael D. Cannon
Independent Director
Independent Director
--
--
Mr. John Michael Climaco, Esq.
Mr. John Michael Climaco, Esq.
Independent Director
Independent Director
--
--
Ms. Elizabeth A. (Liz) Cermak
Ms. Elizabeth A. (Liz) Cermak
Independent Director
Independent Director
--
--
Dr. Joy Yan, LPN
Dr. Joy Yan, LPN
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Klemp (Walter V.)
1.14%
Foster (Jonathan P.)
0.45%
The Vanguard Group, Inc.
0.36%
Geode Capital Management, L.L.C.
0.31%
HRT Financial LP
0.17%
Other
97.58%
Shareholders
Shareholders
Proportion
Klemp (Walter V.)
1.14%
Foster (Jonathan P.)
0.45%
The Vanguard Group, Inc.
0.36%
Geode Capital Management, L.L.C.
0.31%
HRT Financial LP
0.17%
Other
97.58%
Shareholder Types
Shareholders
Proportion
Individual Investor
2.10%
Investment Advisor
0.95%
Investment Advisor/Hedge Fund
0.40%
Family Office
0.07%
Research Firm
0.05%
Corporation
0.04%
Bank and Trust
0.02%
Hedge Fund
0.02%
Other
96.35%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
49
29.68K
1.10%
-41.82K
2025Q3
53
668.05K
1.35%
-868.52K
2025Q2
55
2.48M
8.19%
+1.78M
2025Q1
59
1.58M
6.85%
+964.18K
2024Q4
59
564.93K
7.40%
-45.69K
2024Q3
59
560.84K
19.72%
+96.29K
2024Q2
59
414.10K
17.96%
+17.19K
2024Q1
59
339.02K
15.22%
-103.46K
2023Q4
61
426.81K
19.16%
+202.97K
2023Q3
59
208.67K
10.51%
-20.61K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Klemp (Walter V.)
30.61K
1.14%
+1.00
+0.00%
Dec 11, 2025
Foster (Jonathan P.)
12.13K
0.45%
+1.00
+0.01%
Dec 11, 2025
The Vanguard Group, Inc.
9.60K
0.36%
+8.36K
+675.83%
Sep 30, 2025
Geode Capital Management, L.L.C.
8.33K
0.31%
+7.23K
+656.40%
Sep 30, 2025
HRT Financial LP
4.61K
0.17%
+4.61K
--
Sep 30, 2025
LPL Financial LLC
2.32K
0.09%
+80.00
+3.57%
Sep 30, 2025
IEQ Capital LLC
1.46K
0.05%
+1.46K
--
Sep 30, 2025
Wealth Dimensions Group, Ltd.
800.00
0.03%
+800.00
--
Sep 30, 2025
Picker (Donald H)
671.00
0.02%
--
--
Dec 11, 2025
AnnaMed, Inc.
636.00
0.02%
--
--
Dec 11, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Mar 19, 2024
Merger
15→1
Mar 19, 2024
Merger
15→1
Mar 19, 2024
Merger
15→1
Mar 19, 2024
Merger
15→1
Jan 29, 2021
Merger
6→1
Jan 29, 2021
Merger
6→1
Date
Type
Ratio
Mar 19, 2024
Merger
15→1
Mar 19, 2024
Merger
15→1
Mar 19, 2024
Merger
15→1
Mar 19, 2024
Merger
15→1
Jan 29, 2021
Merger
6→1
Jan 29, 2021
Merger
6→1
Jan 29, 2021
Merger
6→1
Jan 29, 2021
Merger
6→1
FAQs
Who are the top five shareholders of Moleculin Biotech Inc?
The top five shareholders of Moleculin Biotech Inc are:
Klemp (Walter V.) holds 30.61K shares, accounting for 1.14% of the total shares.
Foster (Jonathan P.) holds 12.13K shares, accounting for 0.45% of the total shares.
The Vanguard Group, Inc. holds 9.60K shares, accounting for 0.36% of the total shares.
Geode Capital Management, L.L.C. holds 8.33K shares, accounting for 0.31% of the total shares.
HRT Financial LP holds 4.61K shares, accounting for 0.17% of the total shares.
Klemp (Walter V.) holds 30.61K shares, accounting for 1.14% of the total shares.
Foster (Jonathan P.) holds 12.13K shares, accounting for 0.45% of the total shares.
The Vanguard Group, Inc. holds 9.60K shares, accounting for 0.36% of the total shares.
Geode Capital Management, L.L.C. holds 8.33K shares, accounting for 0.31% of the total shares.
HRT Financial LP holds 4.61K shares, accounting for 0.17% of the total shares.
What are the top three shareholder types of Moleculin Biotech Inc?
The top three shareholder types of Moleculin Biotech Inc are:
Klemp (Walter V.)
Foster (Jonathan P.)
The Vanguard Group, Inc.
Klemp (Walter V.)
Foster (Jonathan P.)
The Vanguard Group, Inc.
How many institutions hold shares of Moleculin Biotech Inc (MBRX)?
As of 2025Q4, 49 institutions hold shares of Moleculin Biotech Inc, with a combined market value of approximately 29.68K, accounting for 1.10% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.25%.
What is the biggest source of revenue for Moleculin Biotech Inc?
In FY2025Q3, the -- business generated the highest revenue for Moleculin Biotech Inc, amounting to -- and accounting for --% of total revenue.
